Methods and results
We randomized in a double-blind, placebo-controlled study 250 STEMI patients to inhale oxygen with (iNO) or without (CON) 80 parts-per-million NO for 4 h following percutaneous revascularization. Primary efficacy endpoint was infarct size as a fraction of left ventricular (LV) size (IS/LV mass ), assessed by delayed enhancement contrast magnetic resonance imaging (MRI). Pre-specified subgroup analysis included thrombolysis-in-myocardial-infarction flow in the infarct-related artery, troponin T levels on admission, duration of symptoms, location of culprit lesion, and intra-arterial nitroglycerine (NTG) use. Secondary efficacy endpoints included IS relative to risk area (IS/AAR), myocardial salvage index, LV functional recovery, and clinical events at 4 and 12 months. In the overall population, IS/LV mass at 48-72 h was 18.0 ± 13.4% in iNO (n = 109) and 19.4 ± 15.4% in CON [n = 116, effect size -1.524%, 95% confidence interval (95% CI) -5.28, 2.24; P = 0.427]. Subgroup analysis indicated consistency across clinical confounders of IS but significant treatment interaction with NTG (P = 0.0093) resulting in smaller IS/LV mass after iNO in NTG-naïve patients (n = 140, P < 0.05). The secondary endpoint IS/AAR was 53 ± 26% with iNO vs. 60 ± 26% in CON (effect size -6.8%, 95% CI -14.8, 1.3, P = 0.09) corresponding to a myocardial salvage index of 47 ± 26% vs. 40 ± 26%, respectively, P = 0.09. Cine-MRI showed similar LV volumes at 48-72 h, with a tendency towards smaller increases in end-systolic and end-diastolic volumes at 4 months in iNO (P = 0.048 and P = 0.06, respectively, n = 197). Inhalation of nitric oxide was safe and significantly increased cGMP plasma levels during 4 h reperfusion. The Kaplan-Meier analysis for the composite of death, recurrent ischaemia, stroke, or rehospitalizations showed a tendency toward lower event rates with iNO at 4 months and 1 year (log-rank test P = 0.10 and P = 0.06, respectively).
Introduction
The extent of myocardial injury is an independent predictor of functional recovery and survival after ST-elevation myocardial infarction (STEMI). 1 Ischaemia reperfusion (I/R) injury accounts for up to 50%
of myocardial damage in STEMI and has been a target for various pharmacological and non-pharmacological, 'conditioning' strategies, although with inconsistent clinical translation. 2 NO-donor compounds have been extensively evaluated in animal models of cardiac I/R injury, with variable effects on MI size and left ventricular (LV) function (for a review, see reference 3). The therapeutic use of NO-donor compounds after MI has been hindered by the fact that these drugs dilate systemic vessels and lower blood pressure. Inhaled NO, in contrast, does not induce prohibitive hypotension and decreases neointima formation in rat carotid arteries subjected to balloon injury, 4 increases coronary artery patency after thrombolysis by decreasing platelet activation, 5 and improves blood flow with decreased leucocyte adhesion in a feline model of intestinal I/R. 6 Importantly, in all three experimental studies, breathing 80 ppm NO had beneficial systemic effects, whereas breathing 20 ppm did not, suggesting a dose-effect relationship. Preclinical studies by our laboratory have shown that inhalation of NO at 80 ppm, during I/R reduces infarct size (IS) and improves functional remodelling in mice and in a more representative porcine model. 7, 8 Inhalation of NO has been successfully administered in patients with pulmonary hypertension because of its selective pulmonary vasodilator capacity 9 and more recently in patients with cardiogenic shock due to right ventricular MI. 10 We therefore investigated whether in patients with timely reperfused STEMI and successful percutaneous coronary intervention (PCI), inhaled NO reduces IS, and improves LV function and structure at 4 months' follow-up.
Methods

Trial design
Nitric oxide for inhalation in ST-elevation myocardial infarction was a randomized, double-blind, placebo-controlled, parallel-group, multicentre, Phase 2 investigator-initiated study of NO for inhalation at 80 ppm vs. placebo in patients with STEMI. Patients were enrolled at four sites in three countries.
Selection of patients
Patients aged 18 years and older were eligible if they had ECG evidence of ST-segment elevation (sum > 0.6 mV in leads I, II, III, AVL, AVF, V1-6) with onset of infarction between 2 and 12 h, and if they had successful restoration of flow following PCI. Patients with heart failure (Killip Class 3) or requiring more than 2 L oxygen to maintain normal arterial saturation were excluded. Patients with prior MI, left bundle branch block, need for urgent coronary artery bypass grafting, or unable to tolerate magnetic resonance imaging (MRI) because of disallowed metallic implants or gadolinium contrast because of advanced renal failure were also excluded.
The Institutional Review Board of the University Hospitals Leuven, the local ethics committees, and the Federal Health Authorities in Belgium, Hungary, and Poland approved the protocol. All patients provided written informed consent. An independent data safety monitoring board (DSMB) assessed patients' safety.
Randomization and treatment masking
Randomization was done centrally at the Leuven Coordinating Center via a telephone interactive voice response system in a 1:1 ratio and blocked by site. All study drug cylinders maintained a blinded label and were stationed in the catheterization suite. Access to the randomization schedule was limited to 1 or 2 study personnel per site who were not involved in any other aspect of the study except for monitoring and reporting of safety parameters. Patients received a 4 h inhalation with 80 ppm NO or placebo (nitrogen gas) supplemented with oxygen through a snug-fitting facemask using a blinded version of the NO-A delivery system (version 1.2.1., Maquet, Ternat, Belgium), which allows continuous real time measurements of NO, O 2 , and NO 2 . Administration of study gas was started upon arrival in the catheterization laboratory with the intent to have study gas flow for 10 min while the interventional team was preparing the coronary intervention. All transmitted safety parameters were only accessible to the DSMB, but not recorded as adverse events to avoid unblinding.
Assessment of safety and efficacy
The primary efficacy objective was MI size as percentage of LV mass at 48-72 h, measured using MRI. Secondary efficacy variables of infarct remodelling included IS as percentage of risk area, (or myocardial salvage index), microvascular obstruction, and myocardial haemorrhage at 48-72 h, and troponin T levels. Secondary efficacy endpoints of LV remodelling included global and regional LV function at 48-72 h and 4 months and changes in LV end-systolic and end-diastolic volumes and sphericity indices over time.
Safety assessments included serial measurements of methaemoglobin levels and NO 2 concentrations in inhaled gas. We simultaneously monitored plasma NOx levels, comprising nitrates, nitrites and S-nitroso compounds, and whole blood nitrite (NO 2 -) levels at baseline, and after 4 h inhalation using ozon-based chemiluminescence analysis (Sievers-NOA280, GEAnalytical Instruments, Boulder, CO, USA). 11 Because NO stimulates cyclic guanosine monophosphate (cGMP) synthesis, we measured plasma cGMP levels using a radio-immunoassay (Alfa-Esar, USA) at baseline and at 4, 24, and 48 h after iNO. We also measured plasma myeloperoxidase (MPO) levels, a marker of neutrophil activation using a Quantikine ELISA (#DMYE00, R&D, Abingdon, UK of death, recurrent ischaemia requiring re-intervention, hospitalization for heart failure and stroke.
Cardiac magnetic resonance imaging acquisition and analysis
Cardiac MRI was performed at 48-72 h on a 1.5 T system to determine IS, presence of microvascular obstruction and intramyocardial haemorrhage, risk area and global LV function, as described. 12 In short, the myocardium at risk was defined by a T2-weighted short-tau inversion-recovery (STIR) fast spin-echo MRI in the cardiac short-axis and represents the sum of the area of myocardial oedema plus the infarct area. Global LV function was assessed using breath-hold steady-state free-precession (SSFP) cine MRI in the cardiac short-axis, vertical-and horizontal long-axis. The presence and extent of microvascular obstruction (MVO) was evaluated 2 to 5 min following contrast-injection of 0.15 mmol/kg of gadolinium diethylenetriamine pentaacetic acid and myocardial necrosis/fibrosis was measured 10 to 20 min later by inversion-recovery gradient-echo technique. To express LV remodelling, a sphericity index was measured by dividing the maximal longitudinal LV diameter (i.e. tip mitral valve to LV apex) by the maximal shortaxis diameter, at end-diastole and end-systole, whereby values approaching 1 indicate increased sphericity.
Statistical analysis
Based on published data, we assumed that in the control group myocardial IS/LV mass , would have a mean and standard deviation of 17.4 ± 10%, with a similar variance in the treatment group. To have statistical power of 80% to detect a 25% reduction in relative IS using a t-test, with type 1 error of 0.05, 84 patients per group are required (PROC POWER in SAS). To allow for a 15% withdrawal rate and a bigger than expected rate of patients with missing MRI at 48-72 h, we randomized 250 patients, with the expectation of having at least 170 evaluable patients. Baseline characteristics and laboratory data are summarized as median (IQR) for continuous variables and number (%) for discrete variables.
The primary analysis set of interest was the full analysis set (FAS), which included all randomized patients who gave informed consent and were diagnosed with STEMI. In addition, analyses were performed on a per protocol set, excluding major protocol violators. Since performing a complete-cases (CC) analysis only might yield biased results, 13 multiple imputation of missing data was done for the analysis of the primary efficacy variable (in accordance with FDA guidelines to account for missing data), using the AregImpute function in R. Continuous primary and secondary efficacy endpoints were analysed using analysis of variance (ANOVA) including factors for treatment and centre. In case of serious violations of the model assumptions, logtransformation was applied. If not appropriate, a Wilcoxon rank-sum test was used. Treatment effect of was estimated by the difference (or ratio, in case of log-transformation) between treatments and presented along with its associated 95% confidence interval (95% CI). For parameters with a baseline measurement, the baseline value was included as covariate in ANOVA.
Binary secondary endpoint data were assessed by means of a v 2 test and treatment effect expressed as odds ratio with associated 95% CIs. Clinical endpoints were analysed in the FAS, whereby event rates are estimated using the Kaplan-Meier methodology and compared using the log-rank test. Comparisons between groups are made using the Pepe-Mori test.
14 The following pre-specified subgroups and interactions were assessed: Thrombolysis-in-Myocardial-Infarction (TIMI) at baseline, culprit lesion, duration of symptoms, troponin T at baseline (positive vs. negative), and use of IC/IA nitroglycerine during procedure. All tests and CIs were twosided and assessed at a significance level of 5%. The SAP was finalized prior to unblinding (see: https://lrd.kuleuven.be/onderzoekscentra/lcc/ nomi/NOMISAP19May2014.pdf).
All analyses were done with SAS (version 9.2) and R2.25.2 for Windows. NOMI is registered with ClinicalTrials.gov (NCT01398384).
Results
Characteristics of the patients, procedural characteristics, and hospital course
We randomized 250 patients at four hospitals in three countries in NOMI, with 123 (49%) patients assigned to 4 h iNO and 127 (51%) assigned to CON (Figure 1) . One iNO-treated patient was excluded because he was later diagnosed with Takotsubo syndrome. The FAS included 249 patients. Demographics are well balanced between groups ( Table 1) . Systolic blood pressure was lower in iNO at baseline and during study drug inhalation, but small absolute differences resolved after treatment cessation. Clinical confounders of IS were not different between groups ( Table 1) . More than two-thirds of patients were admitted within 6 h of symptom onset and 33% within the first 3 h. All patients received aspirin and clopidogrel or prasugrel. Concomitant use of nitro-vasodilators with potential interaction with iNO was similar for both groups and per local protocol ( Table 1) . Use of other pharmacological treatments in STEMI was similar between groups ( Table 2) .
Safety and efficacy
Methaemoglobin levels at 4 h were well below the 5% safety threshold (1.06 ± 0.41% in iNO vs. 0.68 ± 0.31 in CON, P < 0.0001), and NO 2 levels never exceeded 3 ppm. Inhalation of NO did not reduce IS/LV mass , the primary efficacy endpoint, (18.0 ± 13.5% in iNO vs. 19.4 ± 15.4% in CON, estimated treatment effect (95% CI) -1.52 (-5.28; 2.24, P = 0.427; Figure 2A ). In a complete-cases analysis (n = 109 iNO and n = 116 CON) without imputation for the missing primary measure, we observed an identical estimated treatment effect NO-CON (95% CI) of -1.48 (-5.25; 2.29, P = 0.44). The lack of IS reduction was consistent across pre-specified subgroups with potential impact on IS ( Figure 3) . We also did not observe differences between groups in total LV mass or myocardial area at risk (AAR). In patients randomized to iNO, we observed a trend (P = 0.09) towards lower IS/AAR (n = 86 for iNO and n = 82 in CON), which represented a secondary efficacy endpoint ( Figure 2B) . The resulting higher myocardial salvage index (MSI , Table 3 ) is consistent with more viable myocardial segments in iNO (18.4% of all segments with <50% infarct transmurality vs. 11.5% in CON, P = 0.11) and less segments with more than 75% transmurality (50.3% in iNO vs. 56.4% in CON, P = 0.11 using probit model with random intercept).
Cardiac necrosis markers [mean peak high sensitive troponin T concentrations 3.9 (1.5-9.4) ug/L in iNO vs. 3.8 (2.3-7.4) ug/L, in CON, P = 0.96] and incidence of microvascular obstruction at 48-72 h were similar between groups ( Table 3) . Plasma levels of NOx doubled after 4 h iNO but did not change in CON (P < 0.0001, Figure  4A ) and plasma nitrite levels increased by 10% (P < 0.08, 4B). NObased chemiluminescence confirmed comparable NO delivery between study sites (data not shown) and cGMP plasma levels were sustained during 4 h iNO. In contrast, CON patients manifest a swift decline in cGMP levels during early reperfusion (P < 0.0001 vs. iNO, Figure 4C ) and lower levels at 48 h (P = 0.0169 vs. iNO). Left ventricular dimensions at 48-72 h were comparable between groups ( Table 3 ) but LV sphericity indices measured in long-and short-axis at end-systole were higher in iNO (P = 0.024 and P = 0.006 vs. CON, respectively). At 4 months, LV dimensions were smaller in iNO (P = 0.048, Table 3 ).
Mechanism of action, subgroup analysis
The effect of iNO on the primary efficacy endpoint appears to be modulated by peri-procedural use of NTG (P-value for interaction 0.0093, Figure 3 ). We documented a statistically significant heterogeneity of the treatment effect of iNO in patients receiving supplemental NTG, administered via the radial artery (up to 500 lg NTG) or the infarct-related coronary artery (200 lg to 700lg NTG). Nitroglycerine-naive patients (n = 140 or 56%) had a greater than 5% reduction of IS/LV mass after iNO (16 ± 14% vs. 23 ± 18% in CON, P = 0.03). In contrast, patients who received NTG in combination with iNO did not benefit (20 ± 13% vs. 15 ± 9% without iNO, P =0.06). In the same exploratory analysis in NTG-naive patients, IS/ AAR was also significantly smaller after iNO (49.8 ± 28.1%, n = 49 vs. 62.0 ± 28.7% in CON, n = 45, P = 0.027), and was associated with a tendency toward less myocardial haemorrhage (n = 6/60 or 10.0% in iNO vs. n = 14/63 or 22.2% in CON, P = 0.088). Finally, in NTG-naive patients the increases in LV-ESVi and LV-EDVi between baseline and 4 months were markedly smaller in iNO than in CON (P = 0.03 and P = 0.04, respectively). The significant interaction was unexpected and prompted additional analyses. Patients who received the combination of NTG and iNO showed significantly greater myocardial risk areas (measured as oedema volume, Supplementary material online, Figure S1 , P = 0.02 for interaction), and this was not attributable to differences in plasma myeloperoxidase levels, a surrogate for neutrophil activation in STEMI 15 (Supplementary material online, Figure S2 ).
Clinical outcome
There were three deaths in iNO and six in CON during hospital stay (all-cause mortality of 2.5 and 4.7%, respectively), but none were reported to be study treatment-related. After study drug administration, one iNO and three CON patients suffered from reinfarction during index hospitalization. Three CON developed recurrent ischaemia and one CON suffered a thrombotic stroke. During out-of-hospital follow-up, two patients in each group died over the next 4 months, and two more died in CON at 1 year vs. one in iNO.
The Kaplan-Meier analysis of adverse cardiac events showed lower rates for composite clinical endpoints up to 120 days in iNO than in CON, but the differences did not reach statistical significance ( Figure  5 , log-rank test: P = 0.10). Extended follow-up to 1 year confirmed these trends (Supplementary material online, Figure S3 , log-rank test: P = 0.063).
Discussion
The findings of this randomized double-blind, controlled trial indicate that in timely reperfused STEMI, inhalation of 80 ppm NO for 4 h is safe but did not reduce IS relative to LV mass , the primary efficacy endpoint. With respect to secondary efficacy endpoints, the absolute troponin levels, extent of microvascular obstruction and myocardial haemorrhage did not differ by randomized treatment. In contrast, inhaled NO showed a tendency to reduce IS when normalized to LV risk area and was associated with significantly smaller increases in LV dimensions at 4 months' follow-up. Finally, major adverse event rates during hospital stay were similar in both treatment groups and the Kaplan-Meier analysis for the composite of death, recurrent ischaemia, or rehospitalizations showed trends towards lower event rates in iNO at 4 and 12 months' follow-up (log-rank test P = 0.10 and P = 0.06, respectively). In pre-specified subgroup analysis, we observed a marked heterogeneity in the response to inhalation therapy. While the action of iNO was not modified by determinants of IS, we measured a highly statistically significant interaction between iNO and peri-procedural use of the pharmacological NO-donor nitroglycerine (NTG). In NTG-naive patients, comprising 56% of the total population, iNO significantly reduced IS irrespective of the denominator (LV mass or LV risk area), and showed beneficial effects on LV remodelling at 4 months' follow-up. Plasma NOx and nitrate concentrations after 4 h (12) 13 (10) Current smoker, n (%) 57 (47) 56 (44) Peripheral vascular disease, n (%)
7 (6) 5 (4) Stroke, n (%) 3 (2) 5 (4) COPD, n (%) 5 (4) iNO were almost two times as high as baseline levels and associated with significantly increased cGMP levels, an established marker of cardioprotection during ischaemic stress. 16, 17 In contrast, periprocedural use of NTG in CON failed to increase plasma cGMP levels, but as it was not randomized, no conclusions can be made regarding potential cardioprotection by NTG in CON. Our data are consistent with previous observations that iNO in addition to its well-known selective pulmonary vasodilator action 18 may affect remote vascular beds and ischaemic tissues, 19 in part via cGMPmediated effects on cardiac myocytes and circulating cells. 5, 8, 20 In this investigator-initiated trial, we translated for the first time a therapeutic NO-based inhalation strategy with established cardioprotection in preclinical models of myocardial reperfusion injury to STEMI patients. 7, 8, 21 So why did NOMI fail to translate the observed reduction in IS of iNO in experimental models to STEMI patients?
A first potential explanation could be an imbalance in clinical determinants of IS between treatment groups, insufficient IS, suboptimal metrics to test ancillary therapies, or recruitment of patients beyond the 'golden 3 h window of opportunity' 22 for myocardial salvage.
However, in NOMI major clinical modifiers of IS and the extent of LV territory at risk and pre-existing collaterals were similar in iNO and CON patients ( Table 1 and Figure 2B ) and IS was almost twice the 10% threshold of LV mass necessary to explore novel ancillary therapies for STEMI. 1 Whether normalizing IS to LV risk area (Table 3) might represent a more sensitive metric of reperfusion injury, frequently referred to as myocardial salvage index in contemporary clinical trials, is unknown. We also evaluated our data separately in STEMI of less than 3 h duration, but numbers were low (33% of the population) and did not affect the primary efficacy endpoint. 
Placebo better
Results are expressed as [n] mean (SD). Second, the neutral results in the overall NOMI population may relate to pharmacodynamic limitations, insufficient duration of gas flow prior to reperfusion, and insufficient duration of cGMP rise to effectively impact mediators of myocardial injury. All of these may contribute to poor translation of experimental data in the clinic and similar pharmacodynamic limitations likely account for the neutral results following single bolus infusions of nitrite 23 or the mitochondrial pore stabilizing mitofusin compound. 24 Third, the interaction between iNO and nitroglycerine was unexpected and needs to be interpreted in the context of a pre-specified subgroup analysis. In the absence of specific recommendations in the latest ESC guidelines on STEMI, 25 we left the use of intra-arterial NTG at the discretion of the investigator (see Supplementary material online for NOMI study Protocol). A relatively large number of patients were given high doses NTG (44%, most of whom received 500 lg NTG per protocol in one centre during radial access), and manifested a significantly greater risk area and absolute IS (Supplementary material online, Figure S1 ). Whether such combinatorial treatment increases cardiotoxic peroxynitrite intermediates, vascular permeability, and interstitial oedema in the infarct core with more extensive haemorrhage needs further study. Of note, a recent multicentre MRI study in 247 STEMI patients testing powerful vasodilator strategies for I/R injury showed greater IS and worse clinical outcome with adenosine and significantly more microvascular obstruction with intracoronary nitroprusside, a NO-releasing vasodilator. 26 We recognize the limitations of NOMI. First, we studied only a single duration and dose of iNO and cannot exclude different results with extended inhalation or varying dose regimens. A recent double-blind, randomized intervention trial in patients undergoing extracorporeal cardiac bypass for multiple valve surgery reported significant kidney protection in patients receiving 24 h inhalation with 80 ppm NO. 27 Second, peri-procedural intra-arterial use of vasodilatory NO-donor compounds will need to be carefully controlled in future studies. Third, we cannot exclude that oxygen delivery may constitute an independent source of free radicals during reperfusion with potential impact on IS, as recently suggested. 28 Finally, our study was not powered for clinical endpoints of death, stroke, recurrent ischaemia, and revascularizations. Adequately powered clinical outcome studies are indispensable, as recently emphasized by the neutral results of the Phase 3 cyclosporine trial in anterior STEMI, in striking contrast with the 58 patient Phase 2 study. 29 In conclusion, inhalation of 80 ppm NO for 4 h in timely reperfused STEMI was safe, effectively increased plasma cGMP levels but did not reduce IS relative to absolute LV mass at 48-72 h. Promising signals on functional LV remodelling warrant additional pharmacodynamic studies and careful control for the unexpected inhibitory interaction with intra-arterial NO-donor compounds. Ultimately, the impact of inhaled NO on clinical outcome in STEMI must be assessed in adequately powered prospective follow-up studies.
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